3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gynecologic
7
Genitourinary
3
Gastrointestinal
3
Thoracic
2
Head & Neck
2
Dermatologic
2
Breast
2
Sarcoma
1
Plasma cell
1
Other hematologic neoplasm
1
Lymphoid
1
CNS
1
Conditions
Sarcoma
4
Gliosarcoma
4
Glioblastoma
4
Brain Neoplasms
3
Squamous Cell Carcinoma of Head and Neck
2
Ovarian Neoplasms
2
Oligodendroglioma
2
Neoplasm Metastasis
2
Melanoma
2
Liposarcoma
2
Endometrial Neoplasms
2
Carcinosarcoma
2
Carcinoma, Transitional Cell
2
Breast Neoplasms
2
Uterine Cervical Neoplasms
1
Urologic Neoplasms
1
Triple Negative Breast Neoplasms
1
Thyroid Neoplasms
1
Soft Tissue Neoplasms
1
Sarcoma, Alveolar Soft Part
1
Rhabdomyosarcoma
1
Recurrence
1
Prostatic Neoplasms
1
Platinum-Refractory Fallopian Tube Carcinoma
1
Pharyngeal Neoplasms
1
Pancreatic Neoplasms
1
Osteosarcoma
1
Neurofibromatosis 2
1
Neoplasms, Mesothelial
1
Neoplasms
1
Interventions
pembrolizumab
4
Specimen Handling
3
Magnetic Resonance Spectroscopy
3
tislelizumab
2
aflibercept
2
Surveys and Questionnaires
2
Radiotherapy
2
Gene Expression Profiling
2
Fentanyl
2
Docetaxel
2
Diet Therapy
2
Blood Specimen Collection
2
Biopsy
2
trastuzumab deruxtecan
1
toripalimab
1
spartalizumab
1
sargramostim
1
rucaparib
1
pegfilgrastim
1
pazopanib
1
olaparib
1
milademetan
1
entinostat
1
durvalumab
1
ciforadenant
1
ceralasertib
1
cemiplimab
1
avelumab
1
X-Rays
1
Trastuzumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Uterine Cervical Neoplasms
×
Immunoglobulin G
×
Sarcoma
×
Clear all
NCT05269381
2026-03-12
PNeoVCA
Mayo Clinic
Phase 1/2
Recruiting
132 enrolled